Dual HSF1 NRF2 Activator Reduces Protein Misfolding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies are inadequate for effectively addressing protein misfolding, accumulation, and aggregation in diseases mediated by the HSF1 and NRF2 pathways, which are associated with various neurodegenerative and mitochondrial disorders.
Innovation Solution
The compound 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol acts as a dual activator of HSF1 and NRF2 transcription factors, promoting the expression of protein chaperones and reducing protein misfolding and aggregation by activating the HSF1 pathway and enhancing cellular stress responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic strategies are used, then treatment of neurodegenerative diseases is attempted, but they are inadequate for effectively addressing protein misfolding, accumulation, and aggregation
Solution Approach 1:
The compound 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol serves as a dual activator of both HSF1 and NRF2 transcription factors, enabling a single therapeutic agent to address multiple pathological mechanisms including protein misfolding, accumulation, and aggregation through coordinated activation of chaperone pathways and antioxidant responses
2Reliability
If HSF1 pathway is activated to reduce protein misfolding, then chaperone expression increases, but current methods lack effective dual activation of HSF1 and NRF2 pathways
Solution Approach 1:
The patent combines activation of two distinct transcription factor pathways (HSF1 and NRF2) into a single therapeutic mechanism through one compound, simplifying the therapeutic approach while achieving coordinated upregulation of chaperone proteins and antioxidant defenses to comprehensively address protein misfolding and cellular stress
Data Source
AI summary
The invention is directed to 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol for the treatment of diseases mediated by protein misfolding, heat shock factor 1 pathways, or nuclear erythroid 2-related factor 2 pathways.